Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SABS | PRESS-RELEASE | bullish | 7/10 | SAB Biotherapeutics released Phase 1 data for its investigational therapy SAB-142 in established type 1 diabetes (T1D), | Mar 10, 2026 |
| CGEM | PRESS-RELEASE | neutral | 5/10 | Cullinan Therapeutics reported Q4 and full-year 2025 financial results, showing increased R&D spending and a wider net l | Mar 10, 2026 |
| LEGN | PRESS-RELEASE | bullish | 8/10 | Legend Biotech reported strong Q4 and full-year 2025 financial results driven by CARVYKTI® sales, with $555 million in n | Mar 10, 2026 |
| RAPP | PRESS-RELEASE | bullish | 8/10 | Rapport Therapeutics reported its 2025 financial results alongside significant clinical and strategic progress, highligh | Mar 10, 2026 |
| TENX | PRESS-RELEASE | mixed | 6/10 | Tenax Therapeutics reported financial results for 2025, highlighted by a significant increase in R&D and G&A expenses le | Mar 10, 2026 |
| PRLD | PRESS-RELEASE | mixed | 6/10 | Prelude Therapeutics reported its full-year 2025 financial results, showing improved losses and reduced expenses, while | Mar 10, 2026 |
| BNTC | PRESS-RELEASE | bullish | 8/10 | Benitec Biopharma presented updated clinical results for its BB-301 gene therapy in patients with Oculopharyngeal Muscul | Mar 10, 2026 |
| IRD | PRESS-RELEASE | mixed | 6/10 | Opus Genetics reported financial results for 2025, highlighting a reduced net loss, increased cash runway to mid-2028 fo | Mar 10, 2026 |
| ELDN | PRESS-RELEASE | mixed | 6/10 | Eledon Pharmaceuticals announced that the FDA granted Orphan Drug designation to its investigational therapy tegoprubart | Mar 10, 2026 |
| BNTX | PRESS-RELEASE | bearish | 7/10 | BioNTech reported full-year 2025 revenues of €2.87 billion, up 4.3% YoY, but posted a net loss of €1.14 billion (€4.70 d | Mar 10, 2026 |
| BNTX | PRESS-RELEASE | mixed | 7/10 | BioNTech announced that its co-founders, Ugur Sahin and Özlem Türeci, will establish an independent biotechnology compan | Mar 10, 2026 |
| ESPR | PRESS-RELEASE | bullish | 8/10 | Esperion Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenue growing 144% YoY i | Mar 10, 2026 |
| ATAI | PRESS-RELEASE | bullish | 8/10 | AtaiBeckley Inc. announced progress in advancing its lead candidate BPL-003 into Phase 3 trials for treatment-resistant | Mar 10, 2026 |
| INKT | PRESS-RELEASE | bullish | 7/10 | MiNK Therapeutics (INKT) announced a strategic collaboration with C-Further to develop a PRAME-targeted TCR-engineered i | Mar 10, 2026 |
| CLDI | PRESS-RELEASE | bearish | 7/10 | Calidi Biotherapeutics (CLDI) has closed a public offering, raising approximately $6.0 million in gross proceeds by sell | Mar 9, 2026 |
| MLYS | PRESS-RELEASE | bullish | 8/10 | The FDA has accepted Mineralys Therapeutics' New Drug Application (NDA) for lorundrostat, a treatment for adult hyperten | Mar 9, 2026 |
| TNXP | PRESS-RELEASE | bullish | 7/10 | Tonix Pharmaceuticals presented new Phase 3 data at the 2026 AAPM PainConnect Annual Meeting supporting the efficacy and | Mar 9, 2026 |
| CHRS | PRESS-RELEASE | bullish | 8/10 | Coherus Oncology reported strong revenue growth for LOQTORZI, with full-year 2025 net revenue reaching $42.2 million, up | Mar 9, 2026 |
| ARDX | PRESS-RELEASE | neutral | 4/10 | Ardelyx announced the publication of a post-hoc analysis in Therapeutic Advances in Gastroenterology demonstrating that | Mar 9, 2026 |
| MBX | PRESS-RELEASE | bullish | 8/10 | MBX Biosciences announced successful completion of an End-of-Phase 2 meeting with the FDA, confirming the regulatory pat | Mar 9, 2026 |
| ACTU | PRESS-RELEASE | neutral | 4/10 | Actuate Therapeutics announced an expanded preclinical research initiative to evaluate its GSK-3β inhibitor elraglusib i | Mar 9, 2026 |
| TNYA | PRESS-RELEASE | bullish | 7/10 | Tenaya Therapeutics presented preclinical data showing its selective HDAC6 inhibitor TN-301 outperformed the approved DM | Mar 9, 2026 |
| LYEL | PRESS-RELEASE | neutral | 5/10 | Lyell Immunopharma closed an additional $50 million tranche of its private placement, bringing total proceeds to $100 mi | Mar 9, 2026 |
| KROS | PRESS-RELEASE | bullish | 7/10 | Keros Therapeutics presented additional Phase 1 data for rinvatercept (KER-065) at a clinical conference, showing target | Mar 9, 2026 |
| TVGN | PRESS-RELEASE | neutral | 4/10 | Tevogen Bio announced the appointment of interim leaders across key business units as part of its diversified growth str | Mar 9, 2026 |
| KRRO | PRESS-RELEASE | neutral | 6/10 | Korro Bio (KRRO) announced a $85 million PIPE financing led by Venrock Healthcare Capital Partners, with participation f | Mar 9, 2026 |
| TGTX | PRESS-RELEASE | bullish | 7/10 | TG Therapeutics released new post hoc pooled analysis data from its Phase 3 ULTIMATE I and II trials, showing BRIUMVI si | Mar 9, 2026 |
| CRBP | PRESS-RELEASE | mixed | 6/10 | Corbus Pharmaceuticals reported Q4 and full-year 2025 financial results with a wider net loss of $20.6M ($1.25/share) co | Mar 9, 2026 |
| MDCX | PRESS-RELEASE | bullish | 8/10 | Medicus Pharma (MDCX) released updated topline data from its Phase 2 SKNJCT-003 trial showing 73% clinical clearance and | Mar 9, 2026 |
| TRVI | PRESS-RELEASE | bullish | 7/10 | Trevi Therapeutics announced positive feedback from its End-of-Phase 2 meeting with the FDA, confirming the development | Mar 9, 2026 |